The Food and Drug Administration has granted Fast Track designation to SAR402663 for the treatment of neovascular AMD.

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

The amplitude of retinal thickness fluctuations in the early months of anti-VEGF treatment have no effect on later functional outcomes.

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals ...

D Molecular Therapeutics (FDMT) offers attractive growth potential with strong cash reserves and promising late-stage gene ...

Explore the Fight Retinal Blindness! Project, a global registry enhancing VEGF inhibitor treatment outcomes with ...

In a new study, Picture Health's QVT score identified responders and non-responders to immunotherapy and chemoimmunotherapy.